Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma

Tumori. 1992 Dec 31;78(6):380-2. doi: 10.1177/030089169207800607.

Abstract

Twelve patients with malignant pleural mesothelioma were subjected to mitomycin C (MMC) and vindesine (VDS) chemotherapy (MMC 10 mg/m2, i.v., d 1; VDS, 3 mg/m2, i.v., d 1-8, every 4 weeks). No objective response was obtained; 3 (25%) patients had stable disease and 9 (75%) progression of disease. We conclude that MMC plus VDS is an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Mesothelioma / drug therapy*
  • Middle Aged
  • Mitomycin / administration & dosage
  • Pleural Neoplasms / drug therapy*
  • Treatment Outcome
  • Vindesine / administration & dosage

Substances

  • Mitomycin
  • Vindesine